We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Chromogenic Screening Plate Production for E. coli Increased

By LabMedica International staff writers
Posted on 15 Jun 2011
The current outbreak strain of the enterohemorrhagic Escherichia coli (EHCH) in Germany belongs to the Escherichia coli O104 serogroup. More...
Production and distribution of a chromogenic screening plate for rapid detection of extended spectrum β-lactamase-producing (ESBL) organisms, such as E. coli O104, has been increased.

In the past, most outbreaks of hemolytic uremic syndrome (HUS) have been associated with E. coli O157, but the current outbreak strain belongs to the E. coli O104 serogroup. The causative strain produces Shiga toxin 2 and shows high resistance to 3rd generation cephalosporins (due to the ESBL resistance mechanism), as well as broad antimicrobial resistance to, among others, trimethoprim/sulphonamide and tetracycline.

The Oxoid (Basingstoke, England) and Remel (Lenexa, KS, USA) include culture on Oxoid brilliance ESBL agar, which gives results within 24 hours.

Dr. Roger Stephan, Institute for Food Safety and Hygiene, University of Zurich (Switzerland), suggested a diagnostic strategy based on the capability of the VTEC O104 outbreak strain to produce an ESBL. He commented, "Positive fecal samples or food enrichment cultures can be streaked onto Brilliance ESBL agar. On this medium, ESBL-producing E. coli appear as blue colonies after 24 hr. incubation. Suspect colonies will then be confirmed by [polymerase chain reaction] PCR for the vtx genes. Since the prevalence of ESBL-producing E. coli in healthy people and food items should be low, this could really improve chances to isolate the strains responsible for the positive PCR screening."

Other methods of identification include direct toxin detection using the Remel ProSpecT Shiga Toxin E. coli microplate assay; isolation on media, such as Oxoid MacConkey Agar; toxin detection using the Oxoid VTEC-RPLA kit, following growth on Oxoid brain heart infusion agar; antimicrobial susceptibility testing on Oxoid Iso-Sensitest agar or Mueller-Hinton agar with cefpodoxime combination discs and identification using the DuPont Qualicon RiboPrinter microbial characterization system.

Oxoid and Remel are brands of Thermo Fisher Scientific.

Related Links:
Oxoid
Remel
Institute for Food Safety and Hygiene, University of Zurich


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.